phpr 202: antifungal therapy andrew schmelz, pharmd post-doctoral teaching fellow purdue university...

26
PHPR 202: ANTIFUNGAL THERAPY Andrew Schmelz, PharmD Post-Doctoral Teaching Fellow Purdue University School of Pharmacy

Upload: nigel-matthews

Post on 01-Jan-2016

213 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: PHPR 202: ANTIFUNGAL THERAPY Andrew Schmelz, PharmD Post-Doctoral Teaching Fellow Purdue University School of Pharmacy

PHPR 202: ANTIFUNGAL THERAPY

Andrew Schmelz, PharmDPost-Doctoral Teaching Fellow

Purdue University School of Pharmacy

Page 2: PHPR 202: ANTIFUNGAL THERAPY Andrew Schmelz, PharmD Post-Doctoral Teaching Fellow Purdue University School of Pharmacy

FUNGAL INFECTIONS

MYCOSES: an infection caused by fungi• Mild to severe

• Superficial or systemic

Candida albicans• Normal flora

• Overgrowth can lead to infections

• Agents can promote overgrowth

Page 3: PHPR 202: ANTIFUNGAL THERAPY Andrew Schmelz, PharmD Post-Doctoral Teaching Fellow Purdue University School of Pharmacy

SUPERFICIAL INFECTIONS

Candida

• mucous membranes

• moist skin

Dermatophytes

• scalp

• skin

• nails

Page 4: PHPR 202: ANTIFUNGAL THERAPY Andrew Schmelz, PharmD Post-Doctoral Teaching Fellow Purdue University School of Pharmacy

ORAL THRUSH

http://www.nhsdirect.nhs.uk/SelfHelp/conditions/oralthrushchild/_im027.asp

Page 5: PHPR 202: ANTIFUNGAL THERAPY Andrew Schmelz, PharmD Post-Doctoral Teaching Fellow Purdue University School of Pharmacy

TINEA CORPORIS – RING WORM

http://www.emedicine.com/aaem/topic380.htm#section~pictures

Page 6: PHPR 202: ANTIFUNGAL THERAPY Andrew Schmelz, PharmD Post-Doctoral Teaching Fellow Purdue University School of Pharmacy

TINEA CORPORIS

Page 7: PHPR 202: ANTIFUNGAL THERAPY Andrew Schmelz, PharmD Post-Doctoral Teaching Fellow Purdue University School of Pharmacy

ATHLETES FOOT

http://botit.botany.wisc.edu/toms_fungi/feb98.html

Page 8: PHPR 202: ANTIFUNGAL THERAPY Andrew Schmelz, PharmD Post-Doctoral Teaching Fellow Purdue University School of Pharmacy

ATHLETE’S FOOT

Page 9: PHPR 202: ANTIFUNGAL THERAPY Andrew Schmelz, PharmD Post-Doctoral Teaching Fellow Purdue University School of Pharmacy

ATHLETE’S FOOT

Page 10: PHPR 202: ANTIFUNGAL THERAPY Andrew Schmelz, PharmD Post-Doctoral Teaching Fellow Purdue University School of Pharmacy

ONYCOMYCOSIS

Page 11: PHPR 202: ANTIFUNGAL THERAPY Andrew Schmelz, PharmD Post-Doctoral Teaching Fellow Purdue University School of Pharmacy

ONYCOMYCOSIS

Page 12: PHPR 202: ANTIFUNGAL THERAPY Andrew Schmelz, PharmD Post-Doctoral Teaching Fellow Purdue University School of Pharmacy

AGENTS FOR SYSTEMIC & SUPERFICIAL INFECTIONS

Page 13: PHPR 202: ANTIFUNGAL THERAPY Andrew Schmelz, PharmD Post-Doctoral Teaching Fellow Purdue University School of Pharmacy

AZOLE ANTIFUNGALS

THERAPEUTIC USES:• Vary with agents available

MECHANISM OF ACTION:• Damages the fungal cell membrane resulting

in a leakage of cellular components

Page 14: PHPR 202: ANTIFUNGAL THERAPY Andrew Schmelz, PharmD Post-Doctoral Teaching Fellow Purdue University School of Pharmacy

ADVERSE EFFECTS

GI effects: nausea, vomiting, and diarrhea

Rash - (itraconazole)

Liver toxicity

Page 15: PHPR 202: ANTIFUNGAL THERAPY Andrew Schmelz, PharmD Post-Doctoral Teaching Fellow Purdue University School of Pharmacy

MONITORING PARAMETERS

Drug interactions

Liver function tests

Jaundice, dark urine, and pale stools

Hydration

Page 16: PHPR 202: ANTIFUNGAL THERAPY Andrew Schmelz, PharmD Post-Doctoral Teaching Fellow Purdue University School of Pharmacy

SUPERFICIAL AGENTS

Page 17: PHPR 202: ANTIFUNGAL THERAPY Andrew Schmelz, PharmD Post-Doctoral Teaching Fellow Purdue University School of Pharmacy

GRISEOFULVIN

THERAPEUTIC USES:• Superficial fungal infection

• Onychomycosis

MECHANISM OF ACTION:• Stops the fungal cell growth cycle

Page 18: PHPR 202: ANTIFUNGAL THERAPY Andrew Schmelz, PharmD Post-Doctoral Teaching Fellow Purdue University School of Pharmacy

ADVERSE EFFECTS

Transient headaches, nausea, vomiting,and diarrhea

Rash Drowsiness Liver toxicity (rare) Photosensitivity (rare)

Page 19: PHPR 202: ANTIFUNGAL THERAPY Andrew Schmelz, PharmD Post-Doctoral Teaching Fellow Purdue University School of Pharmacy

NYSTATIN

THERAPEUTIC USE:• Treatment of local fungal infections

MECHANISM OF ACTION:• Binds to cell membrane components and

causes leakage of fungal cell components

Page 20: PHPR 202: ANTIFUNGAL THERAPY Andrew Schmelz, PharmD Post-Doctoral Teaching Fellow Purdue University School of Pharmacy

NYSTATIN

ROUTES OF ADMINISTRATION:• oral

• topical

ADVERSE EFFECTS:• well tolerated

• nausea, vomiting, and diarrhea (large oral doses)

• local irritation (topical)

Page 21: PHPR 202: ANTIFUNGAL THERAPY Andrew Schmelz, PharmD Post-Doctoral Teaching Fellow Purdue University School of Pharmacy

TERBINAFINE (Lamisil®)

INDICATION• Onychomycosis

• Topical/localized infections

MECHANISM OF ACTION• Interferes with cell wall synthesis and causes

fungal cell death

ROUTES OF ADMINISTRATION• Oral

• Topically

Page 22: PHPR 202: ANTIFUNGAL THERAPY Andrew Schmelz, PharmD Post-Doctoral Teaching Fellow Purdue University School of Pharmacy

ADVERSE EFFECTS

Rash GI upset Hepatotoxicity Headache Neutropenia Dermatologic

Page 23: PHPR 202: ANTIFUNGAL THERAPY Andrew Schmelz, PharmD Post-Doctoral Teaching Fellow Purdue University School of Pharmacy

TERBINAFINE (Lamisil®)

MONITORING PARAMETERS:• Liver function tests

PATIENT EDUCATION:• Complete full course of therapy

• May be taken with or without food

Page 24: PHPR 202: ANTIFUNGAL THERAPY Andrew Schmelz, PharmD Post-Doctoral Teaching Fellow Purdue University School of Pharmacy

TOLNATATE (Tinactin®)

INDICATIONS:• Topical and localized infections

MECHANISM OF ACTION:• Unknown (may interfere with cell wall

synthesis)

Page 25: PHPR 202: ANTIFUNGAL THERAPY Andrew Schmelz, PharmD Post-Doctoral Teaching Fellow Purdue University School of Pharmacy

TOLNATATE (Tinactin®)

ADVERSE EFFECTS:• Local irritation and burning

PATIENT EDUCATION:• For external use

• Clean and dry thoroughly before use

Page 26: PHPR 202: ANTIFUNGAL THERAPY Andrew Schmelz, PharmD Post-Doctoral Teaching Fellow Purdue University School of Pharmacy

IMPLICATIONS FOR PHYSICAL THERAPY

DISEASE STATE• Systemic infections are serious

• Superficial infections occur commonly

• Educate patients

• Recognize symptoms

• OTC therapies can be considered

DRUG THERAPY• Monitor for adverse effects with systemic agents

• Minimal adverse effects with superficial treatment